Amarin (NASDAQ:AMRN) intends
to increase the promotion and education initiatives regarding VASCEPA
(icosapent ethyl) as the only FDA-approved drug for lowering the
persistent cardiovascular risk beyond statin therapy for high-risk
patients.
Planned promotion and educational efforts include
the sponsorship of continuing medical education, social media-based
communications, and advertisements on television and other forms of
media.
The company also plans increased sponsorship of
investigator-initiated research, such as clinical investigation of
VASCEPA in the treatment of COVID-19.
Amarin is also planning for international expansion.
https://seekingalpha.com/news/3578917-amarin-plans-to-increase-vascepa-awareness
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.